Titan XT automated dispensing system and expansion of the cloud-native OmniSphere platform. “Since joining Omnicell in 2024, Nnamdi has made a significant strategic impact on the Company, working to strengthen our operational foundation, shape our...
WISE's investor base as a strategic partner. This final closing builds on the first closing of the round completed in June 2024, which included a venture debt facility from the European Investment Bank (EIB) supported by InvestEU, alongside an...
strains from Lallemand to support digestive and immune health during the critical early-life period. Since its founding in 2024, NurtureBio works with leading breast milk and microbiome researchers to translate emerging science into accessible...
with a central laboratory-confirmed negative SARS-CoV-2 test at baseline. The trial was conducted from June 2023–September 2024. More than 99% of household contacts tested positive for antibodies against SARS-CoV-2 N (nucleocapsid) or S (spike)...
and Kincell Bio, as well as other leading CDMOs and two Tier 1 pharma companies. Since its commercial launch in December 2024, IRO® has been adopted across R&D, PD and now clinical settings. Ori expects the first INDs for IRO®-manufactured products...
care expenditures." MinuteClinic can also serve as a primary care provider to eligible patients 18 and older. Launched in 2024 and continuing to expand across the U.S., MinuteClinic Primary Care enables providers to identify and manage related...
patients are appropriately identified for targeted therapy." BIZENGRI was first approved under accelerated approval in 2024 in advanced, unresectable or metastatic non-small cell lung cancer and pancreatic adenocarcinoma for patients harboring an...
(HMOs) and targeted probiotic strains to support digestive and immune health in infants and toddlers. Founded in 2024 by Stuart Smith, a parent motivated by firsthand experience, the company collaborates with leading breast milk and microbiome...
by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of...
CK0801 Phase 1 Trial Outcomes Phase 1 results for CK0801 in bone marrow failure syndromes were published in NEJM Evidence (2024). In that study of 9 enrolled patients (4 with aplastic anemia, 4 with myelofibrosis, and 1 with hypoplastic...
from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. Important Information Approved Uses CRENESSITY®...
including Parkinson’s disease and multiple sclerosis. Merz Therapeutics acquired the company's commercial portfolio in 2024. Previously, Dr. Cohen was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology...
and its scientific partners, in which multiple FcγR genes were humanized. Since its launch to the scientific community in 2024, genO-hFcγR has been adopted to advance preclinical programs of biopharmaceutical companies and nonprofit organizations,...
subsequent global regulatory approvals. Interim data from RSV season 1 of the SMART trial were also presented at IDWeek 2024 and published in the New England Journal of Medicine. The SMART trial enrolled infants at increased risk of severe RSV...
treatment options by providing high consistency in drug exposure and a convenient method of administration.2,3 In July 2024, CT-P13 SC received final approval from the European Commission for an additional dosing regimen and dose escalation, which...
12 million) of people who have a chronic infection with HBV. Given the severe consequences of HDV infection, WHO's 2024 Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection recommend that...
supporting data in the appendix, were later published as a Letter to the Editor in the New England Journal of Medicine in 2024. About the GLOW Phase 3 Clinical Trial GLOW is a Phase 3, global, multi-center, double-blind, randomized study assessing...
has long been the standard of care despite its limitations. The expanded product line builds on the success of Fibryga's 2024 FDA approval for AFD, which was supported by the landmark FIBRES study published in JAMA. The study demonstrated that...
efficacy and safety results from the PALISADE study were presented at the European Society of Cardiology (ESC) Congress 2024 and the American Heart Association Scientific Sessions 2024 (AHA24) and simultaneously published in The New England Journal...
available under a softgel capsule dosage form in Canada. Building on Marius’s earlier submission to Health Canada in July 2024, the company is now poised to provide Canadian men and their healthcare providers with an additional treatment option....
